Colon Cancer Clinical Trial

Polyp Detection With The Peerscope Systemâ„¢

Summary

The PeerScope System consists of Peer Medical camera heads, endoscopes, video system, light source and other ancillary equipment. The system is intended for endoscopic diagnosis, treatment and video observation of the digestive tract. The PeerScope system model B is indicated for use for endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients.

Objective:To compare the additional diagnostic yield obtained by using the PeerScope Systemâ„¢ extended view vs. the diagnostic yield obtained by the Standard view colonoscopy.

In addition, time measurements including time to cecum, time for withdrawal and overall procedure time will be analyzed and reported for each group.

View Full Description

Full Description

Design:

Patients who are scheduled for screening, surveillance or diagnostic colonoscopy will be recruited to the study and randomized to one of two groups. Each enrolled subject will undergo two "back-to-back" procedures.

Subjects in Group A (study group) will undergo a Standard view colonoscopy followed immediately by a PeerScope Systemâ„¢ extended view colonoscopy. Subjects in Group B (control group) will undergo a PeerScope Systemâ„¢ extended view colonoscopy followed immediately by a Standard view colonoscopy.

Results from the two groups will be analyzed and compared, with primary outcome measures being detection rates for total polyps and detection rates for adenomas. Secondary outcome measures will include withdrawal time, total procedure time and characteristics of polyps detected, including size and histological results.

Subjects will be followed through a 24 hour and a 7 days telephone interview for analysis of unexpected adverse events. Clinical results will be analyzed using various statistical measures of significance.

Study Design:

Multi-center study with up to 196 patients. No. of Patients:

Up to 196 treated patients will be enrolled into the study. Primary Performance Endpoint:

Standard view colonoscopy adenoma overall detection rate compared to the extended view overall adenoma detection rate using the PeerScope Systemâ„¢
Standard view colonoscopy overall polyp detection rate compared to the extended view overall polyp detection rate using the PeerScope Systemâ„¢.

Safety Analysis:

Incidence of device-related and procedure-related serious adverse events. Incidence of complications using PeerScope Systemâ„¢

Known complications include:

Perforation;
Severe abdominal pain;
Infection;
Bleeding (other than expected minor bleeding due to therapeutic procedures e.g. polypectomy);
Inducing inflammation of diverticulum
Arrhythmia, bradycardia, hypotension, hypoxia
Death

Secondary Endpoints / Other Outcomes:

Performance of therapeutic interventions, such as biopsies, polypectomies, APC etc.
Procedure time. The following will be recorded: a. Time for intubation to the cecum. b. Time for withdrawal from the cecum to the anal verge. c. Total procedure time A stopwatch will be used for stopping the timing of the procedure for any polypectomy performed and then restarting once the polypectomy is completed, meaning that purely procedure time is measured
Sedation dosage
Patient satisfaction. Patient's pain at the end of the procedure will be recorded using VAS scale. Results of 24 hour telephone follow-up to assess for post-procedural patient satisfactory will be recorded on the CRF.

Inclusion criteria:

Subject between the ages of 18 and 70
The patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic workup;
Written informed consent must be available before enrollment in the trial
For women with childbearing potential, adequate contraception

Exclusion criteria:

Patients with a history of colonic resection;
Patients with known (or newly diagnosed) inflammatory bowel disease;
Patients with a personal history of polyposis syndrome;
Patients with suspected chronic stricture potentially precluding complete colonoscopy;
Patients with diverticulitis or toxic megacolon;
Patients with a history of radiation therapy to abdomen or pelvis;
Patients with acute lower GI bleeding
Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject between the ages of 18 and 70
The patient is undergoing colonoscopy for screening, for surveillance in follow-up of previous polypectomy or for diagnostic workup;
Written informed consent must be available before enrollment in the trial
For women with childbearing potential, adequate contraception

Exclusion Criteria:

Patients with a history of colonic resection;
Patients with known (or newly diagnosed) inflammatory bowel disease;
Patients with a personal history of polyposis syndrome;
Patients with suspected chronic stricture potentially precluding complete colonoscopy;
Patients with diverticulitis or toxic megacolon;
Patients with a history of radiation therapy to abdomen or pelvis;
Patients with acute lower GI bleeding
Patients who are currently enrolled in another clinical investigation in which the intervention might compromise the safety of the patient's participation in this study.

Study is for people with:

Colon Cancer

Phase:

Phase 2

Estimated Enrollment:

197

Study ID:

NCT01549535

Recruitment Status:

Completed

Sponsor:

PeerMedical Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

North Shore Gasstroenterology Assoiates, P.C.
NY New York, , United States
Southshore Gasstroenterology, P.C
NY New York, , United States
Carmel Medical Center
Haifa , , Israel
Elisha Medical Center
Haifa , , Israel
The Tel Aviv Sourasky Medical Center
Tel Aviv , , Israel
UMC
Utrecht , , Netherlands

How clear is this clinincal trial information?

Study is for people with:

Colon Cancer

Phase:

Phase 2

Estimated Enrollment:

197

Study ID:

NCT01549535

Recruitment Status:

Completed

Sponsor:


PeerMedical Ltd.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider